The BABAM1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited human cell product designed for loss-of-function studies of the BABAM1 gene in a hepatic adenocarcinoma background. These polyclonal knockout cell populations are generated by introducing targeted gene disruptions in the SK-HEP-1 host line using CRISPR/Cas9, yielding a heterogeneous pool of cells with diverse mutations at the BABAM1 locus. This format provides a robust and reproducible model for studying BABAM1-dependent cellular processes without the limitations of single-clone variability. The product enables investigation of both DNA damage repair and inflammatory signaling pathways.
The parental SK-HEP-1 cell line is derived from the ascitic fluid of a patient with liver adenocarcinoma and displays a mixed epithelial-mesenchymal phenotype, characterized by expression of both epithelial and mesenchymal markers. This unique origin makes it a valuable model for liver cancer research, particularly for studies of tumor heterogeneity, metastasis, and drug resistance. SK-HEP-1 cells are widely employed in hepatocellular carcinoma studies, and their dual phenotype provides a relevant context for evaluating how BABAM1 deficiency impacts tumor cell biology and therapeutic responses.
BABAM1 functions as a scaffolding component of two distinct multiprotein complexes: the BRCA1-A complex and the BRISC complex. In the BRCA1-A complex, BABAM1 is recruited to DNA double-strand breaks (DSBs) through RAP80-mediated recognition of K63-linked ubiquitin chains, where it facilitates the deubiquitination of histone H2A by BRCC36. This activity regulates the retention of 53BP1 at DSB sites and influences repair pathway choice between homologous recombination and non-homologous end joining. In the BRISC complex, BABAM1 mediates the deubiquitination of K63-linked ubiquitin chains on immune signaling adaptors such as TAB2 and TAB3, promoting the activation of NF-??B downstream of receptors like TNFR1 and Toll-like receptors. Consequently, BABAM1 integrates signals from DNA damage sensors like ATM kinase and inflammatory stimuli to coordinate cellular outcomes.
In the context of SK-HEP-1 liver adenocarcinoma cells, BABAM1 knockout provides a pertinent model for dissecting the interplay between genomic instability and inflammatory signaling in liver cancer. Defective BRCA1-A complex function can compromise DSB repair, leading to increased sensitivity to DNA-damaging chemotherapeutics and potential synthetic lethalities. Simultaneously, disruption of BRISC-mediated deubiquitination may attenuate NF-??B-driven pro-inflammatory cytokine production, affecting the tumor microenvironment. Thus, this knockout cell pool enables the study of BABAM1??s dual roles in modulating DNA damage responses and inflammatory pathways, which are both critical in hepatic tumor progression and treatment resistance.
Researchers can employ these polyclonal BABAM1 knockout SK-HEP-1 cells in a variety of functional assays. DNA repair capacity can be assessed via comet assay and immunofluorescence staining for ??H2AX and 53BP1 foci following ionizing radiation or genotoxic insult. Co-immunoprecipitation experiments can verify disrupted BRCA1-A complex assembly. Inflammatory signaling outputs may be quantified by RT-qPCR of pro-inflammatory cytokines or by NF-??B reporter assays after stimulation with TNF-?? or LPS. Flow cytometry facilitates cell cycle and apoptosis analyses under DNA-damaging conditions. These cells are also well-suited for pooled CRISPR screens and drug response profiling. For detailed experimental protocols or product inquiries, please contact Ascent Research.
